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Background: Epitope tags and fluorescent fusion proteins have become indispensable molecular tools for studies
in the fields of biochemistry and cell biology. The knowledge collected on the subdomain organization of the two
subunits of the adhesion complex dystroglycan (DG) enabled us to insert the 10 amino acids myc-tag at different
locations along the α-subunit, in order to better visualize and investigate the DG complex in eukaryotic cells.
Results: We have generated two forms of DG polypeptides via the insertion of the myc-tag 1) within a flexible
loop (between a.a. 170 and 171) that separates two autonomous subdomains, and 2) within the C-terminal domain
in position 500. Their analysis showed that double-tagging (the β-subunit is linked to GFP) does not significantly
interfere with the correct processing of the DG precursor (pre-DG) and confirmed that the α-DG N-terminal domain
is processed in the cell before α-DG reaches its plasma membrane localization. In addition, myc insertion in position
500, right before the second Ig-like domain of α-DG, proved to be an efficient tool for the detection and
pulling-down of glycosylated α-DG molecules targeted at the membrane.
Conclusions: Further characterization of these and other myc-permissive site(s) will represent a valid support for
the study of the maturation process of pre-DG and could result in the creation of a new class of intrinsic
doubly-fluorescent DG molecules that would allow the monitoring of the two DG subunits, or of pre-DG, in cells
without the need of antibodies.Background
Dystroglycan (DG) is a widely expressed transmembrane
protein that connects the extracellular matrix to the
cytoskeleton. It is composed of two subunits, α and β,
encoded by a single gene and expressed as a unique pre-
cursor (pre-DG) that is cleaved into two proteins by an
early post-translational processing [1]. In skeletal muscle
DG forms, together with sarcoglycans, sarcospan, syn-
trophins, and dystrobrevins, the dystrophin-glycoprotein
complex (DGC). This complex links the extracellular
matrix with the actin cytoskeleton and provides stability
to the muscle fiber sarcolemma against contractile forces* Correspondence: andrea.brancaccio@icrm.cnr.it
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reproduction in any medium, provided the or[1]. DG gene knockout in mouse induces premature le-
thality, indicating that DG plays a crucial role during
early embryonic development [2]. Recently, the first mu-
tation associated to a mild form of limb-girdle muscular
dystrophy has been identified in the DG gene [3]. How-
ever, in several other forms of muscular dystrophies, due
to mutations in components of the DGC other than DG,
the membrane localization or the glycosylation pattern
of α-DG are secondarily perturbed [4]. Furthermore, α-
DG can act as a direct receptor for Arenaviruses and, in
complex with laminin, as a receptor for Mycobacterium
leprae [5,6].
Inside the cell, β-DG interacts with dystrophin, which
binds to the actin cytoskeleton, and may act as a scaf-
folding platform for signalling and adaptor proteins [7].
The β-DG extracellular domain has been catalogued as a
“natively unfolded protein”, characterized by the absence
of any well defined three-dimensional structure [8]. Theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation but harbours a series of conserved sites through
which it is capable of binding a plethora of intracellular
adaptor proteins [7]. α-DG, a glycosylated peripheral
membrane protein associated to β-DG via non-covalent
interactions, represents the major link between the
cytoskeleton and the extracellular space, since it binds
several matrix proteins such as laminin and perlecan [1].
α-DG has a dumbbell-like structure characterized by
two globular domains, the N-terminus and C-terminus,
separated by a central mucin-like region [9]. The 3D
structure of its N-terminal domain consists of two sub-
domains that are connected by a flexible region spanning
the 161–180 a.a. portion of the molecule [10].
Functional studies on DG expressed in transfected cul-
tured cells are limited mainly by the scarce availability of
commercial antibodies. However, specific tags (such as
myc, Flag or green fluorescent protein, GFP) terminally
fused to the C-terminal end of the β-DG cytodomain
have been largely used and greatly helped in the visual-
isation of the β-DG subunit [11-14]. On the other hand,
it is often much more difficult to detect signals relative
to α-DG, due to its extensive and heterogeneous glyco-
sylation. In this study, we show how the α subunit can
be tagged with the myc epitope inserted at specific sites
within its N-terminal domain in order to better analyze
intracellular and membrane-targeted α-DG and its pos-
sible processing within cells.
Results
Insertion of a myc probe within the α-DG subunit
We have used a murine DG cDNA cloned in the pEGFP-
N1 vector as a starting template for the insertion of the
myc epitope in different positions within α-DG (Figure 1).
Specifically, a 10 amino acids myc-epitope (EQKLI-
SEEDL) was intercalated within α-DG in order to
visualize by Western blot and fluorescence microscopy
the α-DG subunit, that in 293-Ebna cells is very poorly,
when not at all, recognized by commercial antibodies.
We generated different DG constructs characterized
by a myc-tagged α-subunit and the C-terminus of the β-
subunit fused to the intrinsic fluorescent protein GFP.
The insertion of the myc tag was rationally based on the
3D structure of the N-terminal domain of α-DG [10]; we
attempted three different positions within such region,
namely DG-A29-mycGFP, DG-A60-mycGFP and DG-
A170-mycGFP (Figure 1). Molecular modeling of the N-
terminus of α-DG (based on our available 1U2C PDB
structure, [10]) with myc intercalated between positions
170/171, shows that the fold of the α-DG subunit should
be totally preserved, as the insertion of the tag does not
influence either the local secondary structure or the ter-
tiary structure of the two subdomains (Figure 2). We did
not attempt further simulations since our reference (i.e.the recombinant domain-based structure) did not in-
clude the α-DG very N-terminal portion (including
Ala29, which represents the C-terminal end of the DG
signal peptide), and was mostly unstructured at the level
of Ala60 [10]. Moreover, on the basis of our recent mo-
lecular model of the C-terminal domain of α-DG [15], a
myc-tag was also inserted in position K500 (resulting in
the construct DG-K500-mycGFP), right before the region
of the C-terminal domain of α-DG predicted to adopt an
immunoglobulin-like fold (see Figure 1).
A technical note that can be of some general interest is
that the insertion of 30 nucleotides encoding the myc-tag
to produce the DG-A60-mycGFP and DG-A170-mycGFP
constructs was readily obtained using the Quick Change
mutagenesis kit (Stratagene, USA). All the DNA manipu-
lations and steps taken for intercalating the 30 bp myc-
sequences (including the complementary 78 bp primers
necessary for producing the two aforementioned con-
structs) are extensively described in the Materials and
Methods section.
Mature α-DG and myc-tagged α-DG N-terminal domain
can be enriched from trasfected 293-Ebna cells
The four constructs were used to transiently transfect
293-Ebna cells, and the resulting exogenous DG mole-
cules were first analyzed by Western blot. It has to be
reminded that when total protein extracts are examined,
the exogenous β-DG is readily observed: the presence of
the EGFP at the C-terminal domain of β-DG increases
its molecular mass by about 27 kDa, making the en-
dogenous β-DG (43 kDa) easily distinguishable from the
exogenous one (70 kDa).
Western blot analysis of total protein extracts showed
that the insertion of a myc-tag in the construct DG-A29-
mycGFP partially inhibited the post-translational proces-
sing of the DG precursor, while DG-A60-mycGFP was
poorly expressed (data not shown). However, DG-A170-
mycGFP and DG-K500-mycGFP were correctly cleaved
into α- and β-DG, indicating that the insertion of a myc-
tag in these positions does not alter, nor interfere with,
the functional maturation of pre-DG (Figure 3A).
Using an anti-myc antibody, we detected a 34 kDa
band in the total protein extracts of DG-A170-mycGFP
transfected cells that is likely to correspond to the myc-
tagged α-DG N-terminal domain processed in the ma-
ture protein. In fact, it was proposed that the N-terminal
domain of α-DG undergoes an early proteolytic reaction
in position 312 mediated by furin, a RER convertase
[17,18]. Accordingly, the 34 kDa band is observable in
protein total extracts of DG-A170-mycGFP but not in
those of DG-K500-mycGFP (Figure 3B). To test whether
the myc-tag inserted in the N-terminal domain can be
used to specifically isolate and visualise such proteolytic
product, we used magnetic beads linked to an anti-myc
Figure 1 A schematic cartoon of the domain organization of DG showing the insertion of the myc-tag in different sites within the α-
DG subunit. The myc-tag was inserted at the end of the signal peptide (A29), before the first residue of the solved 3D structure (PDB:1U2C) of
the N-terminal region of α-DG (A60), in the middle of the flexible loop connecting the two sub-domains (Ig-like and S6-like) featured within the
N-terminal region of α-DG (A170) and right before a second Ig-like domain identified within the α-DG C-terminus (K500). The C-terminal region of
β-DG is fused to GFP in the myc-tagged constructs. DG numeral system is based on the majority of mammals sequences available, including the
human one, all starting from an additional Met, followed by Arg (1-MRMSV-5), with respect to the murine one (3-MSV-5).
Morlacchi et al. BMC Biochemistry 2012, 13:14 Page 3 of 8
http://www.biomedcentral.com/1471-2091/13/14antibody to immunoprecipitate the α-DG N-terminus
from a total protein extract of cells transfected with DG-
A170-mycGFP. As shown in Figure 3C, a single band
of 34 kDa is purified from the total protein extract,
which is likely to correspond to the myc-tagged N-
terminal domain. Indeed, the cleavage can be specifically
prevented by adding CMK, a furin inhibitor, to the cells
(Figure 3C) [18]. This result fully confirms that the pro-
teolytic breakdown at the α-DG N-terminus mediated
by furin takes place downstream of position 170 [17,18].
No signals referring to the typical broad pattern of
highly glycosylated α-DG were detected in the total pro-
tein extracts of DG-K500-mycGFP transfected cells using
both anti-αDG (IIH6 and VIA1-4, data not shown) and
anti-myc antibodies (Figure 3B). This data suggests that
in the total protein extract the level of myc-tagged α-DG
is below the range detectable by antibodies, as it is often
observed with endogenous α-DG when using commer-
cially available antibodies (data not shown).
However, when α-DG was enriched by immunoprecipi-
tation with an anti-myc antibody conjugated to magnetic
beads, a 120 kDa band representing the fully glycosylated
α-DG subunit expressed in embryonic kidney cells [19]
was clearly revealed by Western blotting using an anti-
myc-HRP-conjugated antibody (Figure 4A). Such immu-
noprecipitated α-DG was not reactive to IIH6 and VIA1-4
antibodies (data not shown), indicating that in Ebna-293
cells α-DG is not recognized by these commercial anti-
bodies, as already shown by other works [11,20].
Other interesting aspects of our K500-myc tagged
α-DG, pointing to its full functionality, are i) that it
can still bind to β-DG, as the β-subunit can be enrichedin immunoprecipitation with an anti-myc antibody
(Figure 4B) and ii) it is still able to pull-down ERp57, a
novel potential DG interactor [21]. Such evidences con-
firm that α-DG-K500-myc shares similar structural and
functional properties with wild-type α-DG. Moreover, it
is noteworthy that also in a different cell type, likely char-
acterized by a different glycosylation pattern of α-DG,
the DG-K500-mycGFP construct encodes for two DG
subunits that appear to be highly expressed and correctly
targeted to the plasma membrane (LNCaP prostate
cancer cells, Steve Winder, personal communication).Confocal microscopy of myc-tagged DG-GFP constructs
Confocal microscopy of fixed cells transfected with the
myc-tagged constructs was used to analyze the subcellu-
lar localization of the DG complex (Figure 5). Both the
myc-tagged constructs were able to originate a β-DG-
GFP product that was exported to the plasma membrane
as suggested by the analysis of the GFP-intrinsic fluores-
cence signals in Figure 5A (DG-A170-mycGFP) and
Figure 5B (DG-K500-mycGFP) that are similar to the
wild-type β-DG-GFP (data not shown, see [20]).
There is nearly no detectable c-myc immunostaining
signal at the plasma membrane for DG-A170-mycGFP,
for which instead more signal is observed around the
nucleus, presumably at the ER and Golgi compartments
(Figure 5A). As mentioned above, this experimental
evidence strongly points toward the full shedding of the
N-terminal portion of α-DG [17]. On the contrary,
DG-K500-mycGFP displays a clear plasma membrane
staining when cells are stained with the anti-c-myc
Figure 2 3D-model of the N-terminus of α-DG with the myc-tag
inserted in position 170. The whole N-terminal region of murine
α-DG (positions 3–313 referring to the general numeration based on
the human sequence), including i) the 160-180 endogenous loop
region that in our 3D structure could not be solved due to its
flexibility [10], and ii) an exogenous 10 a.a. myc-tag inserted
between positions 170 and 171, was modeled using the widely used
server I-TASSER, which allows ab initio modeling of small proteins
[16]. The presence of the myc-tag (reported in yellow) does not alter
the intrinsic flexibility of this region, which on the contrary remains
rather disorganized. Such an insertion is therefore unlikely to
influence either the secondary or the tertiary structures of the two
surrounding α-DG subdomains, so that the overall folding of the
whole α-DG subunit is preserved. Color code for structural elements:
light blue (β-strand), red (α-helix), grey (turn or loop) and yellow
(myc tag).
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geted to the plasma membrane (Figure 5B).
Discussion
Myc-tagging the α-DG domains: finding the best
structurally permissive site(s) for an improved
biochemical and microscopic detection
Short linear epitope tags that confer specific targeting
properties, including an enhanced affinity for interactors(proteins, enzymes, antibodies), or the possibility for a
facilitated detection by fluorescence microscopy, are ex-
tensively used as fundamental tools in cellular biochem-
istry analyses.
Like other investigators, we have fused to the C-
terminal end of the β-DG cytoplasmic domain the green
fluorescence protein (GFP), which allowed to better iden-
tify the β-subunit of DG [20]. The data collected so far
show that the presence of the chimaeric 27 kDa GFP
subunit does not compromise or influence the adhesion
and signalling function of β-DG anyhow, implying that
no major steric hindrance effects can be ascribed to the
intrinsically fluorescent partner. On the other hand, the
α-subunit of DG is much less easy to detect, due to its
extensive glycosylation shell that can prevent the binding
of antibodies, depending on the high negative charge of
the syalic terminations or simply on their hindrance. In
fact, only few commercial antibodies that recognise un-
disclosed carbohydrate epitopes protruding from the α-
DG subunit are currently available, and sometimes they
generate faint signals, if at all, especially on some trans-
fected cell lines. Such behaviour could depend on the fact
that every cell line has its own repertoire of glycosyl-
transferases, so that exogenous DG molecules could be
differently decorated with sugars depending on the cell
line employed.
In this paper we have focussed our attention on α-DG
produced in the commonly used 293-Ebna cell line. The
knowledge that we have accumulated on the domain
organization of α-DG was fundamental in the rational
search of a permissive site to be used for the insertion of
a specific tag (a 10 amino acids myc-epitope) for better
detecting and visualising the α-subunit of DG in trans-
fected cells without disrupting the structural
organization of the DG-complex.
The insertion of the myc-tag was rationally designed
based on the three-dimensional structure of the N-
terminal domain of α-DG [10] (Figure 2) and on the
model of its C-terminal domain [15]. The X-ray struc-
ture of the N-terminal domain, spanning the amino
acids 30–315, showed the presence of two sub-domains:
the first identified as an Ig-like domain, between amino
acids 60–160, and the second resembling the ribosomal
RNA-binding protein S6, between amino acids 181–315,
with a very flexible region (161–180) interconnecting the
two sub-domains. The tag was then inserted at the end
of the signal peptide of pre-DG (DG-A29-mycGFP) [22],
and before and after the Ig-like domain (DG-A60-
mycGFP and DG-A170-mycGFP). On the basis of a model
of the C-terminal domain of α-DG, the myc tag was also
inserted in position K500, just in front of a region pre-
dicted to fold as an Ig-like domain (DG-K500-mycGFP).
Western blot analysis of total protein extracts of trans-
fected cells showed that the presence of the myc-tag at
Figure 3 Western blot of total protein extracts of cells overexpressing DG-A170-mycGFP and DG-K500-mycGFP. The analysis of total
protein extracts was carried out using antibodies directed against β-DG (A) and the myc-tag (B and C). A) The insertion of the myc-tag at sites
A170 and K500 does not alter the expression and processing of DG, as shown by the presence of a band at 60 kDa, corresponding to β-DG-
GFP (black arrow). Asterisk refers to endogenous β-DG. B) Western blot with an anti-myc antibody did not detect any signals in a total protein
extract of cells transfected with K500-mycGFP, while a band at 34 kDa (black arrow), which is likely to correspond to the α-DG N-terminal fragment
harbouring the myc-tag, was present in a total protein extract of cells transfected with A170-mycGFP. C) Immunoprecipitation with magnetic
beads conjugated with an anti-myc antibody of the processed N-terminal domain of α-DG (EL) from a total protein extract of cells transfected
with DG-A170-mycGFP (TOT). The N-terminal cleavage is inhibited by CMK added to the cells (TOT +CMK).
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sion levels of DG and the processing of the DG precur-
sor into the two subunits (Figure 3). Notably, the
insertion of the myc tag at the C-terminal domain of α-
DG (DG-K500-mycGFP) allowed to visualize the α-DG
subunit in Western blot after immunoprecipitation and
in fluorescence microscopy (Figures 4A and 5B, respect-
ively). This result is particularly interesting due to theFigure 4 Enrichment of the myc-tagged α-DG from total
protein extracts. Immunoprecipitation of the myc-tagged α-DG (EL)
with magnetic beads conjugated with an anti-myc antibody from a
total protein extract of cells transfected with DG-K500-mycGFP (TOT).
A) Western blot was performed using an anti-myc-HRP conjugated
antibody, which detects a band at 120 kDa. TOT, total protein
extracts; NT, not transfected cells. B) Western blot performed using
an anti β-DG antibody showing that α-DG-K500-myc still binds to β-
DG since β-DG-GFP is found within the anti-myc pulled-down
fraction. In cells transfected with DG-K500-mycGFP , the band at
60 kDa corresponds to β-DG-GFP (black arrow), while in not
transfected cells the band at 43 kDa (asterisk) corresponds to
endogenous β-DG.typical difficulties in recognizing α-DG with the plethora
of commercial antibodies directed towards some of its
undefined carbohydrate epitopes. Moreover, the inser-
tion of 10 amino acids does not perturb the interaction
between α- and β-DG, and the myc-tagged α-DG is still
able to pull-down ERp57 [21], suggesting that the tagged
α-DG is functionally similar to wild-type α-DG [20].
Besides, the insertion of myc-tag can be used success-
fully to enrich the N-terminal domain of α-DG from cel-
lular extracts. Recently, it was proposed that the N-
terminal domain of α-DG would serve as a recognition
and anchoring site for the glycosyltransferase LARGE
and, upon glycosylation, would be then cleaved in the
mature protein [17,18]. The corresponding fragment was
found in the medium of different cell types and circulat-
ing in the human serum, although in very limited
amounts [23].
In our Western blot experiments carried out on total
protein extracts derived from cells transfected with the
DG-myc tagged constructs, a band running at 34 kDa
is observable in DG-A170-mycGFP but not in DG-K500-
mycGFP (see arrow in Figure 3B and C). In total cellular
extracts this band is likely to represent some cleaved
myc-tagged N-terminal portion of α-DG that engulfs the
cytosol/ER and/or is ready to be delivered outside the
cells via some exocytosis-based pathway. Our initial
attempts to collect the band from the medium culture
failed, due to the very low amount of protein available
(data not shown). However, exploiting anti-myc anti-
bodies immobilised on magnetic beads, we showed that
the myc-tag inserted in position A170 can be used to
specifically collect increased amounts of the processed
N-terminal domain of α-DG. In fact, a single band of
Figure 5 Confocal microscopy of myc-tagged DG constructs
expressed in 293-Ebna cells. GFP and c-myc immunofluorescence
staining of cells transfected with DG-A170-mycGFP A), and DG-K500-
mycGFP B), constructs. GFP specific signal at 488 nm excitation,
c-myc immunostaining at 543 nm excitation and their merge are
shown. A XY confocal section is represented for each signal. A) and
B) The GFP signal (green) shows that from both the DG-A170-myc
GFP and DG-K500-mycGFP constructs originate a β-DG-GFP protein
that localizes at the plasma membrane in a way reminiscent of the
wild-type β-DG-GFP. A) C-myc immunostaining shows no plasma
membrane signal in cells transfected with the DG-A170-mycGFP
construct, but only intense diffused and punctuated perinuclear
(red) signals. B) The DG-K500-mycGFP construct instead shows a
strong plasma membrane localized c-myc immunostaining (red),
whose localization is fully confirmed by the yellow-orange colour
observable in the merged images.
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transfected cells and we will use it for further biochem-
ical characterization, including mass spectrometry
(Figure 3B and C). Indeed, in a recent paper reporting
the characterization of recombinant murine α-DG, in
the absence of an appropriate N-terminal tag the
Authors could not find any peptides derived from the
entire N-terminal portion of α-DG [24]. All considered,
the rational design of myc-intercalated α-DG constructsthat we have carried out based on our extensive expertise
on domain organization and structural aspects of α-DG
[10,15] proved to be a very powerful strategy for improv-
ing the detection of α-DG molecules, and their possible
fragments, within cells or in cellular extracts.
Conclusions: towards an intrinsic doubly
fluorescent dystroglycan?
In the future novel chimaeric constructs will be also
tested in additional cell lines, in order to further validate
their properties and to check whether any differences
within the glycosylation or maturation pathway of DG
would influence their stability.
Some of the identified insertion sites (or even add-
itional ones) still represent good candidates for further
molecular manipulations that ambitiously aim at obtain-
ing a DG carrying two different intrinsic fluorophores,
thus creating a doubly-fluorescent molecule [25,26].
Such a strategy will make it possible to analyze the be-
havior of DG in living cells without all the potential arte-
facts that can arise from antibody staining.
A doubly fluorophore-tagged DG could be very useful
in the investigation, by confocal microscopy technolo-
gies, of the dynamic details of the pre-DG maturation
and N-terminal α-DG processing in living cells (along
the ER-Golgi-Plasma Membrane route), and in any case
could be of help in studies aimed at determining the tar-
geting of the two DG subunits (or of pre-DG) at the
plasma membrane or at other subcellular compartments.
In fact, measuring the fluorescence resonance energy
transfer (FRET) between the two fluorophore-tagged DG
subunits would enable to monitor interactions of these




The full-length cDNA encoding for murine DG was
used as a template to generate by the gene splicing by
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overlapping DNA constructs which allowed, by a third
PCR reaction (see below), to insert the c-myc epitope
upon the triplet encoding for K500.














The EcoRI restriction sites and the c-myc epitope se-
quence are given in bold type. The two GENE SOEing
final products were obtained by a third PCR reaction






The PCR products were subsequently cloned in the
pEGFP-N1 vector (Clontech, USA).
The DG-A170-mycGFP were directly produced using
the QuikChange site-directed mutagenesis kit (Strata-
gene, USA) with the following primers (the c-myc epi-









All the final constructs were verified by automated
sequencing.
Cell culture and transfection
293-Ebna cells were grown in DMEM supplemented
with antibiotics and 10 % (v/v) fetal calf serum. About
20 μg of vector containing the constructs were used to
transfect 293-Ebna cells using the calcium phosphate
method. Briefly, DNA was mixed with 125 mM CaCl2
and BES-buffered saline, containing 50 mM BES,
280 mM NaCl and 150 mM Na2HPO4. The DNA cal-
cium phosphate complex was added to the cells. After
24 h, cells were collected for Western blot analysis. Forthe inhibition of furin, 20 μM CMK was added to the
cells for 24 h after transfection. For fluorescence and
confocal microscopy analyses, 5 μg of each construct
were transiently transfected into 293-Ebna cells, and
after 24 hours cells were fixed with 4 % (v/v) paraformal-
dehyde at room temperature for 10 min.
Total protein extraction and Western blot
Cells transfected with the four constructs, with empty
pEGFP and wild-type DG-GFP were lysed with PBS
containing 1 % Triton X-100 and protease inhibitors
(Roche, Switzerland), then centrifuged at 14000 rpm for
10 min at 4 °C. After 1 h of incubation at 4 °C, 20 μg
of each lysate was resolved on a 10 % SDS-PAGE. For
Western blot analysis, proteins were transferred to
nitrocellulose and probed with the following antibodies
diluted in the PBS containing 0.05 % Tween 20 and 3 %
BSA: anti β-DG (Novocastra, UK) (1:50) and anti c-
myc-HRP conjugated (Miltenyi Biotec., Germany)
(1:5000). The nitrocellulose was incubated with
peroxidase-conjugated secondary antibody (Sigma,
USA) diluted 1:7000 (anti-mouse); the reactive products
were revealed using the luminol-based ECL system
(Pierce, USA).
Immunoprecipitation
All the steps required for immunoprecipitation were car-
ried out using the μMACS™Epitope Tag Protein Isolation
Kit (Miltenyi Biotec., Germany) , following the manufac-
turer’s instructions. Briefly, 1 ml of total protein extract
of transfected cells was incubated with 50 μl of magnetic
beads conjugated with an anti-myc antibody (Miltenyi
Biotec., Germany) for 30 min at room temperature.
After several washes, the adsorbed protein was eluted
with 50 μl of sample buffer, incubated at 99○C and run
on a 10 % SDS-PAGE followed by Western blot analysis
with an anti-myc antibody-HRP conjugated (Miltenyi
Biotec., Germany).
Confocal microscopy
Transiently transfected 293-Ebna cells were fixed and
permeabilized in PBS containing 0.1 % Triton X-100 at
room temperature for 10 min followed by incubation
with the anti c-myc antibody (Sigma, USA) diluted
1:1000 in PBS containing 0.1 % Triton X-100. After sev-
eral washes the cells were incubated with a secondary
antibody conjugated to rhodamine (Invitrogen, USA)
(1:500), imaged with a confocal laser scanning system
(TCS-SP2, Leica Microsystems, GmbH, Wetzlar,
Germany) and analysed with ImageJ programs (http://
rsbweb.nih.gov/ij/). Laser excitation at 488 nm of the
sample was followed by an excitation at 543 nm to col-
lect emission signals from GFP and rhodamine conju-
gated antibodies, respectively.
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